Crescent Biopharma, Inc.
CBIO
$18.00
$0.724.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -90.42% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -90.42% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -90.42% | -- | |||
| SG&A Expenses | 7.61% | 31.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -74.82% | 295.35% | |||
| Operating Income | 72.97% | -253.46% | |||
| Income Before Tax | 74.24% | -267.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 74.80% | -275.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 74.80% | -275.49% | |||
| EBIT | 72.97% | -253.46% | |||
| EBITDA | 73.03% | -253.63% | |||
| EPS Basic | 82.54% | -216.39% | |||
| Normalized Basic EPS | 82.16% | -209.54% | |||
| EPS Diluted | 82.54% | -216.39% | |||
| Normalized Diluted EPS | 82.16% | -209.54% | |||
| Average Basic Shares Outstanding | 44.35% | 18.68% | |||
| Average Diluted Shares Outstanding | 44.35% | 18.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||